The Screening of microRNAs in Chronic Myeloid Leukemia: A Clinical Evaluation.
Denise Kusma WosniakiAnelis Maria MarinRafaela Noga OliveiraGabriela Marino KoerichEduardo Cilião MunhozJoão Samuel de Holanda FariasMiriam Perlingeiro BeltrameDalila Luciola ZanetteMateus Nobrega AokiPublished in: International journal of molecular sciences (2024)
Chronic myeloid leukemia (CML) is a type of leukemia whose main genetic marker is the reciprocal translocation that leads to the production of the BCR::ABL1 oncoprotein. The expression of some genes may interfere with the progression and development of leukemias. MicroRNAs are small non-coding RNAs that have the potential to alter the expression of some genes and may be correlated with some types of leukemia and could be used as biomarkers in the diagnosis and prognosis of patients. Therefore, this project carried out an analysis of microRNA-type plasma biomarkers in patients with chronic myeloid leukemia at unique points, including follow-up analysis of patients from the Erasto Gaertner Hospital. 35 microRNAs were analyzed in different cohorts. Inside those groups, 70 samples were analyzed at unique points and 11 patients in a follow-up analysis. Statistically different results were found for microRNA-7-5p, which was found to be upregulated in patients with high expression of the BCR::ABL1 transcript when compared to healthy controls. This microRNA also had evidence of behavior related to BCR::ABL1 when analyzed in follow-up, but strong evidence was not found. In this way, this work obtained results that may lead to manifestations of a relationship between miR-7-5p and chronic myeloid leukemia, and evaluations of possible microRNAs that are not related to this pathology.
Keyphrases
- chronic myeloid leukemia
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- genome wide
- acute myeloid leukemia
- prognostic factors
- clinical evaluation
- emergency department
- healthcare
- peritoneal dialysis
- gene expression
- risk assessment
- quality improvement
- transcription factor
- rna seq
- acute lymphoblastic leukemia
- patient reported
- drug induced
- tyrosine kinase
- human health
- adverse drug